10-[3-(N-benzyl-N-methylamino)propyl]phenothiazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 10-[3-(N-benzyl-N-methylamino)propyl]phenothiazine
• 英文别名: N-benzyl-N-methyl-3-phenothiazin-10-ylpropan-1-amine
• 化学式: C₂₃H₂₄N₂S
• 分子量: 360.523
• InChiKey: FIKKAIJRVLNWOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  31.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-甲基苄胺 在 sodium hydride 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 10-[3-(N-benzyl-N-methylamino)propyl]phenothiazine
  参考文献：
  名称：

  Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands

  摘要：

  Sigma 1 receptors are associated with neurodegenerative and psychiatric disorders. These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents. The involvement of these receptors has also been observed in neuropathic pain and cancer. Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clinical trials. Thus the development of sigma 1 ligands is of interest to a new generation of drugs. Previous work in our lab underlined the potency of benzannulated bicyclic compounds as interesting ligands. Herein the work was extended to a series of novel tricyclic compounds. Carboline- and phenothiazine-derivated compounds were designed and synthesized. In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (K-i = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.10.053

文献信息

• Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27
  申请人：TECHNISCHE UNIVERSITAET DRESDEN

  公开号：US10940150B2

  公开（公告）日：2021-03-09

  The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.

  本发明涉及新型HSP27抑制剂，特别是根据通式（VI）、（VII）或（VII）的胸腺嘧啶衍生物和根据式（V）的吩噻嗪衍生物，以及它们作为选择性抑制热休克蛋白HSP27（HSPB1）的药物的用途，特别是用于治疗癌症或囊性纤维化，所述抑制剂在较低的微摩尔或亚微摩尔活性成分浓度范围内对HSP27具有特别有利的活性。
• EFFICIENT INHIBITION OF HSP27
  申请人：TECHNISCHE UNIVERSITAET DRESDEN

  公开号：US20170216297A1

  公开（公告）日：2017-08-03

  The present invention relates to novel HSP27 inhibitors, in particular purine derivatives according to general formula (I) or (II) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP2.
• THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27
  申请人：TECHNISCHE UNIVERSITAET DRESDEN

  公开号：US20180207160A1

  公开（公告）日：2018-07-26

  The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.
• Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands
  作者：Marion Donnier-Maréchal、Paul-Emmanuel Larchanché、Delphine Le Broc、Christophe Furman、Pascal Carato、Patricia Melnyk

  DOI：10.1016/j.ejmech.2014.10.053

  日期：2015.1

  Sigma 1 receptors are associated with neurodegenerative and psychiatric disorders. These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents. The involvement of these receptors has also been observed in neuropathic pain and cancer. Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clinical trials. Thus the development of sigma 1 ligands is of interest to a new generation of drugs. Previous work in our lab underlined the potency of benzannulated bicyclic compounds as interesting ligands. Herein the work was extended to a series of novel tricyclic compounds. Carboline- and phenothiazine-derivated compounds were designed and synthesized. In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (K-i = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells. (C) 2014 Elsevier Masson SAS. All rights reserved.